Day: November 10, 2022

Exploring Atypical Fluorine-Hydrogen Bonds and Their Effects on Nucleoside Conformations was written by O’Reilly, Daniel; Stein, Robin S.; Patrascu, Mihai Burai; Jana, Sunit Kumar; Kurian, Jerry; Moitessier, Nicolas; Damha, Masad J.. And the article was included in Chemistry – A European Journal in 2018.Category: pyrimidines The following contents are mentioned in the article:

The ability of fluorine to serve as a hydrogen-bond acceptor has been debated for many years. Short fluorine-hydrogen contacts are thought to play a key role in stabilizing some complex supramol. systems. To directly probe the existence of fluorine-hydrogen bonds, we have performed NMR spectroscopy and computational modeling on a series of C2′-fluorinated nucleosides. Specifically, quantum mechanics/mol. mechanics (QM/MM) anal. and [19F,1H] HMBC NMR experiments provided direct evidence for a C-H…F hydrogen bond in a 2′-F,4′-C-α-alkyL-ribonucleoside analog. This interaction was also supported by QTAIM and NBO analyses, which confirmed a bond critical point for the C-H…F interaction (0.74 kcal mol-1). In contrast, although conformational anal. and NMR experiments of 2′-deoxy-2′-fluoro-arabinonucleosides indicated a close proximity between the 2′-fluorine and the H6/8 protons of the nucleobase, mol. simulations did not provide evidence for a C-H…F hydrogen bond. This study involved multiple reactions and reactants, such as 4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (cas: 56632-83-8Category: pyrimidines).

4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (cas: 56632-83-8) belongs to pyrimidine derivatives. Pyrimidine is an aromatic heterocyclic organic compound similar to pyridine. Drugs having the pyrimidine motif have manifested to exhibit gratifying biological activity like anticancer, antiviral, anti-inflammatory, antibacterial, and antihypertensive activities.Category: pyrimidines

56632-83-8;4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one;The future of 56632-83-8;New trend of C9H12FN3O4;function of 56632-83-8

In vitro and in vivo anti-HSV activities of 1-β-D-arabinofuranosyl-E-5-(2-halogenovinyl)uracil was written by Machida, Haruhiko; Sakata, Shinji; Kuninaka, Akira; Yoshino, Hiroshi. And the article was included in International Congress Series in 1982.Safety of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione The following contents are mentioned in the article:

E-5-(2-bromovinyl)arabinosyluracil (I) [77181-69-2] and E-5-(2-chlorovinyl)arabinosyluracil  [77181-70-5] were slightly more effective against herpes simplex virus-1 (HSV-1) infection, but much less effective against HSV-2 infection as compared to 5-vinylarabinosyluracil  [74886-33-2]. Thus, substitution of a H with a halogen at C-2 of the vinyl group increased the anti-HSV-1 activity of vinylarabinosyluracil but weakened its anti-HSV-2 activity. The anti-HSV-1 activity of I was almost equal to that of E-5-(2-bromovinyl)-2′-deoxyuridine BV-dUrd) [69304-47-8], 2′-fluoro-5-iodoarabinosylcytosine  [69123-90-6], and 2′-fluoro-5-methylarabinosyluracil  [69256-17-3]. I was less inhibitory to the growth of HEL-F cells than BV-dUrd. Thus, replacement of the deoxyribose moiety by arabinose in 5-vinyl and 5-halogenvinyl derivatives of 2′-deoxyuridines seems to weaken anticellular activity without significant loss of antiviral activity. The selectivity of I against HVS-1 was confirmed in terms of inhibition of DNA formation in HSV-1 infected cells. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Safety of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. Pyrimidine also found in many synthetic compounds such as barbiturates and the HIV drug, zidovudine. A Cu-catalyzed and 4-HO-TEMPO-mediated [3 + 3] annulation of commercially available amidines with saturated ketones enables an efficient and facile synthesis of structurally important pyrimidines via a cascade reaction of oxidative dehydrogenation/annulation/oxidative aromatization.Safety of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Integrating Dynamic Positron Emission Tomography and Conventional Pharmacokinetic Studies to Delineate Plasma and Tumor Pharmacokinetics of FAU, a Prodrug Bioactivated by Thymidylate Synthase was written by Li, Jing; Kim, Seongho; Shields, Anthony F.; Douglas, Kirk A.; McHugh, Christopher I.; Lawhorn-Crews, Jawana M.; Wu, Jianmei; Mangner, Thomas J.; Lo Russo, Patricia M.. And the article was included in Journal of Clinical Pharmacology in 2016.Application In Synthesis of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione The following contents are mentioned in the article:

FAU, a pyrimidine nucleotide analog, is a prodrug bioactivated by intracellular thymidylate synthase to form FMAU, which is incorporated into DNA, causing cell death. This study presents a model-based approach to integrating dynamic positron emission tomog. (PET) and conventional plasma pharmacokinetic studies to characterize the plasma and tissue pharmacokinetics of FAU and FMAU. Twelve cancer patients were enrolled into a phase 1 study, where conventional plasma pharmacokinetic evaluation of therapeutic FAU (50-1600 mg/m2) and dynamic PET assessment of 18F-FAU were performed. A parent-metabolite population pharmacokinetic model was developed to simultaneously fit PET-derived tissue data and conventional plasma pharmacokinetic data. The developed model enabled separation of PET-derived total tissue concentrations into the parent drug and metabolite components. The model provides quant., mechanistic insights into the bioactivation of FAU and retention of FMAU in normal and tumor tissues and has potential utility to predict tumor responsiveness to FAU treatment. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Application In Synthesis of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. The pyrimidine ring system has wide occurrence in nature as substituted and ring fused compounds and derivatives. As nucleotides in DNA and RNA, pyrimidine nucleotide derivatives have a wide range of biological applications. For example, pyrimidine derivatives are useful in DNA repair studies involving cancer and epigenetics.Application In Synthesis of 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

Nucleosides. 133. Synthesis of 5-alkenyl-1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)cytosines and related pyrimidine nucleosides as potential antiviral agents was written by Perlman, Michael E.; Watanabe, Kyoichi A.; Schinazi, Raymond F.; Fox, Jack J.. And the article was included in Journal of Medicinal Chemistry in 1985.Reference of 56632-83-8 The following contents are mentioned in the article:

The preparation of 1-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)cytosines with a halovinyl or vinyl substituent at C-5 (I, R = CH:CHBr, CH:CHI, CH:CH2) was accomplished from the corresponding 5-iodo and/or 5-chloromercuri nucleoside analog with use of Li2PdCl4- and Pd(OAc)2-mediated coupling reactions. Thiation of the benzoylated derivative of 2′-fluoro-5-ethyl-ara-U followed by S-methylation and then ammonolysis provided I (R = Et). 5-Ethynyl-2′-fluoro-ara-C and 5-ethynyl-2′-fluoro-ara-U (II; R1 = CCH; Z = NH, O) were obtained from the perisilylated 5-iodo nucleosides by PdII/CuI catalyzed coupling with (trimethylsilyl)acetylene. Most of the new compounds showed activity in vitro against both HSV-1 and HSV-2, as did the known corresponding 5-alkenyluracil nucleosides synthesized earlier. The therapeutic indexes of these compounds are in some cases superior to those of 2′-fluoro-5-methyl-ara-U. Moderate antileukemic activity was observed in vitro for the 5-alkynyl and 5-vinyl compounds The competition of these compounds with thymidine for viral-induced thymidine kinases was also studied. This study involved multiple reactions and reactants, such as 4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (cas: 56632-83-8Reference of 56632-83-8).

4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (cas: 56632-83-8) belongs to pyrimidine derivatives. Heterocyclic compounds bearing the pyrimidine core are of tremendous interest as they constitute an important class of natural and synthetic compounds exhibiting diverse useful biological activities that hold attractive potential for clinical translation as therapeutic agents in alleviation of a myriad of diseases. Pyrimidine derivatives have been used in a wide variety of pharmaceuticals including general anesthetics, anti-epilepsy medication, anti-malaria medication, drugs for treating high blood pressure, and HIV medication.Reference of 56632-83-8

56632-83-8;4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one;The future of 56632-83-8;New trend of C9H12FN3O4;function of 56632-83-8

Substrate/inhibitor specificities of human deoxycytidine kinase (dCK) and thymidine kinases (TK1 and TK2) was written by Kierdaszuk, Borys; Krawiec, Krzysztof; Kazimierezuk, Zygmunt; Jacobsson, Ulla; Johansson, Nils G.; Munch-Petersen, Birgitte; Eriksson, Staffan; Shugar, David. And the article was included in Advances in Experimental Medicine and Biology in 1998.Reference of 56632-83-8 The following contents are mentioned in the article:

Substrate/inhibitor specificities of nucleoside analogs with modified sugar moieties towards highly purified deoxycytidine kinase (dCK) and thymidine kinases (TK1 and TK2) from human leukemic spleen have been examined Substrate activities of cytosine nucleosides vs. dCK were as follows: 2′-fluoro-dC > 2′-O-methyl-C > araC > 2′-fluoro-2′-deoxy-araC > 3′-O-methyl-dC = 3′-fluoro-2′,3′-ddC > cytosine β-L-riboside > 2′,3′-ddC > C= 1-(4-hydroxy-1,2-butadienyl)-cytosine (cytallene) = 2′-azido-dC. Modified purine nucleosides were only feeble substrates: ara-A > 2′-fluoro-2′-3′-dideoxy-ara-A = 2′-O-methyl-A. With TK1 and TK2, similar sugar-modified analogs of dU and dT were feeble substrates. Surprisingly α-dT was a relatively good substrate, as well some β-L-ribonucleosides. Several 5′-substituted analogs of dC were good non-substrate inhibitors of dCK and, to a lesser extent, of TK2. The overall data are relevant to the role of these enzymes in “”activation”” (by phosphorylation) of nucleoside analogs with antiviral and antitumor activities. This study involved multiple reactions and reactants, such as 4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (cas: 56632-83-8Reference of 56632-83-8).

4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (cas: 56632-83-8) belongs to pyrimidine derivatives. The pyrimidine nitrogenous bases are derived from the organic compound pyrimidine through the addition of various functional groups. As nucleotides in DNA and RNA, pyrimidine nucleotide derivatives have a wide range of biological applications. For example, pyrimidine derivatives are useful in DNA repair studies involving cancer and epigenetics.Reference of 56632-83-8

56632-83-8;4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one;The future of 56632-83-8;New trend of C9H12FN3O4;function of 56632-83-8

Drug resistant and hypersensitive herpes simplex virus mutants: isolation and application to dissection of the pol locus was written by Coen, Donald M.; Chiou, Henry C.; Fleming, H. Edward Jr.; Leslie, Laurel K.; Retondo, Margaret J.. And the article was included in UCLA Symposia on Molecular and Cellular Biology, New Series in 1984.Category: pyrimidines The following contents are mentioned in the article:

Herpes simplex virus mutants resistant to antiviral drugs and aphidicolin are readily isolated in a single-step selection procedure. However, it was found that mutants resistant to one drug are often not substantially cross-resistant to others suggesting possible solutions to potential clin. resistance. Repeated plaque purification has proven essential for such analyses. Previous studies have identified PAA-, ACG-, and araA-resistance mutations in the DNA polymerase (pol) locus. Mutations conferring hypersensitivity to araA, PAA, FMAU, FIAU, BVdU, 2’NDG, and aphidicolin (Aph) were identified and several of these were mapped to the pol locus. The existence of either type of mutation in the pol locus implies that polymerase is a target for the drugs or otherwise mediates drug-sensitivity. Addnl., cross-resistance patterns of the mutants suggest that polymerases capable of discriminating against one nucleoside analog are incapable of discriminating against closely related compounds Mutations conferring altered sensitivity to the same drug map at different locations in the pol locus. Anal. of these mutations should aid in the functional dissection of the polymerase. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Category: pyrimidines).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. Pyrimidines are isomeric with two other forms of diazines: pyridazine, with the nitrogen atoms in the 1 and 2 positions; and pyrazine, with the nitrogen atoms in the 1 and 4 positions. Pyrimidine derivatives have been used in a wide variety of pharmaceuticals including general anesthetics, anti-epilepsy medication, anti-malaria medication, drugs for treating high blood pressure, and HIV medication.Category: pyrimidines

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

The promoted synthesis of minoxidil by magnetic nanoparticles of cobalt ferrite (CoFe2 O4) as a heterogeneous reusable catalyst was written by Eisavi, Ronak; Ahmadi, Fatemeh; Zeynizadeh, Behzad; Kouhkan, Mehri. And the article was included in Turkish Journal of Chemistry in 2019.Related Products of 35139-67-4 The following contents are mentioned in the article:

Minoxidil (2,4-diamino-6-piperidinopyrimidine 3-oxide) was primarily recognized as a drug for reducing vascular resistance to blood flow. It was later introduced as a more important medicine for topical stimulation of hair growth and baldness reverting as well as treatment of androgenic alopecia through increasing prostaglandin endoperoxide synthesis. In this study, magnetic nanoparticles (MNPs) of spinel ferrites (MFe2 O4, M = Co, Ni, Fe, Cu, and Zn) via solid-state grinding procedure were prepared and then characterized using X-ray diffraction, SEM, transmission electron microscopy, vibrating sample magnetometer, and Fourier transform IR techniques. The prepared nanoferrites were utilized as efficient and green heterogeneous catalysts for N -oxidation of 2,6-diamino-4-chloro-pyrimidine with H2 O2 in refluxing ethanol giving 2,6-diamino-4-chloro-pyrimidine N -oxide as a starting material for the synthesis of 2,4-diamino-6-piperidinopyrimidine 3-oxide (minoxidil). Among the examined nanoferrites, CoFe2 O4 MNPs exhibited prominent catalytic activity giving the product in 95% yield within 60 min. Moreover, the reusability of nano-CoFe2 O4 was examined for 6 consecutive cycles without significant loss of catalytic activity and magnetic property. This study involved multiple reactions and reactants, such as 2,6-Diamino-4-chloropyrimidine-1-oxide (cas: 35139-67-4Related Products of 35139-67-4).

2,6-Diamino-4-chloropyrimidine-1-oxide (cas: 35139-67-4) belongs to pyrimidine derivatives. The aromatic compound pyrimidine, and its derivatives, are ubiquitous in nature. They are found in nucleic acids, vitamins, amino acids, antibiotics, alkaloids, and a variety of toxins. We all know its importance to life – pyrimidine and purine bases are included in the structure of DNA and RNA.Related Products of 35139-67-4

35139-67-4;2,6-Diamino-4-chloropyrimidine-1-oxide;The future of 35139-67-4;New trend of C4H5ClN4O;function of 35139-67-4

Simultaneous determination of 1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl) uracil (FAU) and 1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl) 5-methyluracil (FMAU) in human plasma by liquid chromatography/tandem mass spectrometry was written by Wiegand, Richard; Wu, Jianmei; Shields, Anthony F.; LoRusso, Patricia; Li, Jing. And the article was included in Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences in 2012.Computed Properties of C10H13FN2O5 The following contents are mentioned in the article:

A liquid chromatog. coupled with tandem mass spectrometry (LC-MS/MS) assay was developed and validated for simultaneous determination of 1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl) uracil (FAU) and its active metabolite 1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl) 5-methyluracil (FMAU) in human blood plasma. FAU and FMAU were extracted from plasma samples using solid-phase extraction with Waters Sep-Pak Vac C18 cartridge. Chromatog. separation was achieved on a Waters Atlantis T3 C18 column with a gradient mobile phase consisting of MeOH and water with 0.45% formic acid (volume/volume) running at a flow rate of 0.2 mL/min. The analytes were monitored by triple quadrupole mass spectrometer under pos. ionization mode. The lower limit of quantitation (LLOQ) was 10 and 2 ng/mL for FAU and FMAU in plasma, resp. Calibration curves were linear over FAU and FMAU plasma concentration range of 10-2000 and 2-1000 ng/mL, resp. The intra-day and inter-day accuracy and precision were within the generally accepted criteria for bioanal. method (<15%). The method was successfully employed to characterize the plasma pharmacokinetics of FAU and FMAU in cancer patients receiving 1-h i.v. infusion of FAU 50 mg/m2. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Computed Properties of C10H13FN2O5).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. The pyrimidine ring system has wide occurrence in nature as substituted and ring fused compounds and derivatives. Drugs having the pyrimidine motif have manifested to exhibit gratifying biological activity like anticancer, antiviral, anti-inflammatory, antibacterial, and antihypertensive activities.Computed Properties of C10H13FN2O5

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3

A novel radiochemical approach to 1-(2′-deoxy-2′-[18F]fluoro-β-D-arabinofuranosyl)cytosine (18F-FAC) was written by Meyer, Jan-Philip; Probst, Katrin C.; Trist, Iuni M. L.; McGuigan, Christopher; Westwell, Andrew D.. And the article was included in Journal of Labelled Compounds and Radiopharmaceuticals in 2014.Name: 4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one The following contents are mentioned in the article:

18F-FAC (1-(2′-deoxy-2′-[18F]fluoro-β-D-arabinofuranosyl)-cytosine) is an important 2′-fluoro-nucleoside-based positron emission tomog. (PET) tracer that has been used for in vivo prediction of response to the widely used cancer chemotherapy drug gemcitabine. Previously reported synthetic routes to 18F-FAC have relied on early introduction of the 18F radiolabel prior to attachment to protected cytosine base. Considering the 18F radiochem. half-life (110 min) and the tech. challenges of multi-step syntheses on PET radiochem. modular systems, late-stage radiofluorination is preferred for reproducible and reliable radiosynthesis with in vivo applications. Herein, we report the first late-stage radiosynthesis of 18F-FAC. Cytidine derivatives with leaving groups at the 2′-position are particularly prone to undergo anhydro side-product formation upon heating because of their electron d. at the 2-carbonyl pyrimidone oxygen. Our rationally developed fluorination precursor showed an improved reactivity-to-stability ratio at elevated temperatures 18F-FAC was obtained in radiochem. yields of 4.3-5.5% (n = 8, decay-corrected from end of bombardment), with purities ≥98% and specific activities ≥63 GBq/μmol. The synthesis time was 168 min. This study involved multiple reactions and reactants, such as 4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (cas: 56632-83-8Name: 4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one).

4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one (cas: 56632-83-8) belongs to pyrimidine derivatives. Pyrimidine also found in many synthetic compounds such as barbiturates and the HIV drug, zidovudine. Drugs having the pyrimidine motif have manifested to exhibit gratifying biological activity like anticancer, antiviral, anti-inflammatory, antibacterial, and antihypertensive activities.Name: 4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one

56632-83-8;4-Amino-1-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one;The future of 56632-83-8;New trend of C9H12FN3O4;function of 56632-83-8

Rapid Quantitative Determination of L-FMAU-TP from Human Peripheral-Blood Mononuclear Cells of Hepatitis B Virus-Infected Patients Treated with L-FMAU by Ion-Pairing, Reverse-Phase, Liquid Chromatography/Electrospray Tandem Mass Spectrometry was written by Lee, Jaeick; Yoo, Byung-Chul; Lee, Hyo-Suk; Yoo, Hee-Won; Yoo, Hye-Hyun; Kang, Min Jung; Kim, Dong-Hyun. And the article was included in Therapeutic Drug Monitoring in 2005.Application of 69256-17-3 The following contents are mentioned in the article:

The purpose of this study was to develop an anal. method for the determination of 2′-fluoro-5-methyl-β-l-arabinofuranosyl uracil triphosphate (L-FMAU-TP) in human peripheral blood mononuclear cells (PBMCs), and its application in the determination of cellular levels of L-FMAU-TP in PBMCs isolated from patients treated with 2′-fluoro-5-methyl-β-l-arabinofuranosyl uracil (L-FMAU). An ion-pairing liquid chromatog. (IPC) method, coupled with neg. ion electrospray ionization tandem mass spectrometry (ESI-MS/MS), was developed for the accurate and repeatable detection of L-FMAU-TP, with a limit of detection of 1.6 pmol/106 cells. The calibration curve for L-FMAU-TP was linear over the concentration range 1.6 to 80 pmol/106 cells. The intra- and inter-day precision was lower than 11.2%, and the accuracy was between 97.1 and 106.9%. When applied to the determination of L-FMAU-TP in PBMCs isolated from HBV-infected patients undergoing L-FMAU treatment, the levels reached a steady state concentration 4 wk after daily single oral administration of 20 mg L-FMAU, and these levels were maintained for up to 12 wk, but then decreased 12 wk after drug cessation. The terminal half-life of L-FMAU-TP in PBMCs after drug cessation was estimated to be 15.6 days. This study involved multiple reactions and reactants, such as 1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3Application of 69256-17-3).

1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione (cas: 69256-17-3) belongs to pyrimidine derivatives. The aromatic compound pyrimidine, and its derivatives, are ubiquitous in nature. They are found in nucleic acids, vitamins, amino acids, antibiotics, alkaloids, and a variety of toxins. Drugs having the pyrimidine motif have manifested to exhibit gratifying biological activity like anticancer, antiviral, anti-inflammatory, antibacterial, and antihypertensive activities.Application of 69256-17-3

69256-17-3;1-((2R,3S,4R,5R)-3-Fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione;The future of 69256-17-3;New trend of C10H13FN2O5;function of 69256-17-3